
    
      This is a Phase IIa, double blind, randomized, parallel group, placebo controlled multi
      centre study which will include 36 subjects in total and 18 subjects in each treatment group
      are needed for this study.

      AZD8154 or placebo is administered via nebulizer QD for 10 consecutive days. This study will
      include 5 sites in the AllerGen Clinical Investigator Collaborative (CIC) group in Canada.
    
  